The hyaluronidase PH20 degrades HA, disrupting HACD44TGF-/SMAD2/3 signaling and demonstrating antifibrotic potential beyond its current ophthalmic applications (177)
The US Preventive Services Task Force voiced concern for these potential side effects in children, as well as an excessive focus on weight instead of health
As the body adjusts to a lower weight and new eating patterns, weight loss naturally slows and may reach a steady point
In the key Phase 3 ATTAIN-1 trial published in the New England Journal of Medicine in 2025, once-daily orforglipron 36 mg produced mean body weight reductions of 11.2% at 72 weeks in adults with obesity, with nearly 55% of participants achieving at least 10% weight loss and 36% achieving 15% or more
S dng cho bnh nhn lm p da, chng lo ha, h tr iu tr nm, tn nhan, sng mt, gim ngc chy s s dng 1-2-3 vin/ ngy sau n du tr s dng 60-90 ngy ty thuc tng bnh nhn